Clinical Research Directory
Browse clinical research sites, groups, and studies.
Silymarin Effects on Fatty Liver in Type 2 Diabetics
Sponsor: University of Mosul
Summary
This nine-month prospective clinical trial evaluated the effects of adding a daily oral dose of 480 mg of silymarin (milk thistle) to standard multi-drug therapy in 120 adult patients with Type 2 diabetes. Compared to the control group receiving standard care alone, participants taking silymarin showed significant reductions in liver enzymes (AST and ALT), improvements in their lipid profiles, and reduced liver fat (steatosis) confirmed via FibroScan imaging. While renal function remained stable and the supplement proved safe, silymarin did not lead to changes in overall liver fibrosis stages over the study duration. Ultimately, the trial demonstrates that silymarin can serve as a safe and effective adjunctive supplement to help manage hepatic steatosis and liver inflammation in patients with Type 2 diabetes.
Official title: Effect of Silymarin (Milk Thistle) on Hepatic Fibrosis, Glycemic Control and Biochemical Parameters in Type 2 Diabetic Patients
Key Details
Gender
All
Age Range
25 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-01-02
Completion Date
2026-06-01
Last Updated
2026-10-13
Healthy Volunteers
No
Conditions
Interventions
Silymarin (Silybum marianum)
Participants received a daily oral dose of 480 mg of silymarin as an add on supplementation for 9 months.
Locations (1)
Outpatient Clinic, Ibn Sina Teaching Hospital
Mosul, Iraq